Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3913 Target Snapshot

Complement C1s subcomponent · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
200Compounds
29Assays
0Approved Drugs
204.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Complement C1s subcomponent shows approved-linked disease relevance led by Anemia, Hemolytic, Autoimmune. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P09871. Start with Anemia, Hemolytic, Autoimmune, then reuse UniProt P09871 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Anemia, Hemolytic, Autoimmune, then reuse UniProt P09871 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Anemia, Hemolytic, Autoimmune

Complement C1s subcomponent shows approved-linked disease relevance led by Anemia, Hemolytic, Autoimmune. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Anemia, Hemolytic, Autoimmune because it currently carries approved-linked support. Linked drugs include SUTIMLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Complement C1s subcomponent as ChEMBL target CHEMBL3913, mapped to UniProt P09871. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Complement C1s subcomponent
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3913
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P09871
Complement C1s subcomponent
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Complement C1s subcomponent is the right protein anchor across sources, using UniProt P09871 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Anemia, Hemolytic, Autoimmune is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameComplement C1s subcomponent
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP09871
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelComplement C1s subcomponent
UniProt AccessionP09871
Component TypeProtein
Sequence Length688 aa

Complement C1s subcomponent

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Complement C1s subcomponent, mapped to UniProt P09871. Sequence length is 688 aa.

Mapped IDP09871
Review nameComplement C1s subcomponent
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Complement C1s subcomponent shows approved-linked disease relevance led by Anemia, Hemolytic, Autoimmune. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Anemia, Hemolytic, Autoimmune
1 linked drug · 1 direct · 1 efficacy
Linked drugSUTIMLIMAB
Approved-linked Approved
cold agglutinin disease
1 linked drug · 1 direct · 1 efficacy
Linked drugSUTIMLIMAB
Approved-linked Approved
hemolysis
1 linked drug · 1 direct · 1 efficacy
Linked drugSUTIMLIMAB
Approved-linked Approved
hereditary angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Late clinical Phase III
angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugHUMAN C1-ESTERASE INHIBITOR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Anemia, Hemolytic, Autoimmune because it currently carries approved-linked support. Linked drugs include SUTIMLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAnemia, Hemolytic, Autoimmune
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
Assay Mix

Activity Type Distribution

IC5050.0
KI154.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2220483 8.8 IC50 1.6 Preclinical
CHEMBL5723340 8.8 IC50 1.6 Preclinical
CHEMBL4244141 8.22 Ki 6.0 Preclinical
CHEMBL5435382 8.15 IC50 7.0 Preclinical
CHEMBL205904 8.0 Ki 10.0 Preclinical
CHEMBL4242095 7.96 Ki 11.0 Preclinical
CHEMBL399284 7.85 Ki 14.0 Preclinical
CHEMBL401398 7.7 Ki 20.0 Preclinical
CHEMBL377090 7.7 Ki 20.0 Preclinical
CHEMBL403782 7.66 Ki 22.0 Preclinical
Distribution

pChEMBL Value Distribution

14
5.0
18
5.5
41
6.0
21
6.5
16
7.0
10
7.5
3
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

29
Total Assays
145
Tested Compounds
2
Assay Types
Binding — 27 assays, 145 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 23 128 6.3
cell-based format 3 16 6.0
assay format 1 1 7.3
Functional — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 1 8.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine